Shilpa Medicare Limited (SHILPAMED) - Total Assets
Based on the latest financial reports, Shilpa Medicare Limited (SHILPAMED) holds total assets worth Rs34.95 Billion INR (≈ $377.98 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore SHILPAMED debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Shilpa Medicare Limited - Total Assets Trend (2006–2025)
This chart illustrates how Shilpa Medicare Limited's total assets have evolved over time, based on quarterly financial data. See Shilpa Medicare Limited shareholders equity for net asset value and shareholders' equity analysis.
Shilpa Medicare Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Shilpa Medicare Limited's total assets of Rs34.95 Billion consist of 29.8% current assets and 70.2% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs6.66 Million | 0.8% |
| Accounts Receivable | Rs4.41 Billion | 13.3% |
| Inventory | Rs3.48 Billion | 10.5% |
| Property, Plant & Equipment | Rs16.75 Billion | 50.6% |
| Intangible Assets | Rs5.18 Billion | 15.7% |
| Goodwill | Rs462.31 Million | 1.4% |
Asset Composition Trend (2006–2025)
This chart illustrates how Shilpa Medicare Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shilpa Medicare Limited market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shilpa Medicare Limited's current assets represent 29.8% of total assets in 2025, a decrease from 63.5% in 2006.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2025, up from 0.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 15.0% in 2006.
- Asset Diversification: The largest asset category is property, plant & equipment at 50.6% of total assets.
Shilpa Medicare Limited Competitors by Total Assets
Key competitors of Shilpa Medicare Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Shilpa Medicare Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.36 | 1.74 | 1.68 |
| Quick Ratio | 0.79 | 1.08 | 1.14 |
| Cash Ratio | 0.03 | 0.03 | 0.00 |
| Working Capital | Rs2.78 Billion | Rs3.65 Billion | Rs3.73 Billion |
Shilpa Medicare Limited - Advanced Valuation Insights
This section examines the relationship between Shilpa Medicare Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.51 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 7.0% |
| Total Assets | Rs33.11 Billion |
| Market Capitalization | $1.32 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shilpa Medicare Limited's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shilpa Medicare Limited's assets grew by 7.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shilpa Medicare Limited (2006–2025)
The table below shows the annual total assets of Shilpa Medicare Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs33.11 Billion ≈ $358.04 Million |
+7.03% |
| 2024-03-31 | Rs30.93 Billion ≈ $334.52 Million |
+6.52% |
| 2023-03-31 | Rs29.04 Billion ≈ $314.05 Million |
+0.99% |
| 2022-03-31 | Rs28.75 Billion ≈ $310.97 Million |
+9.02% |
| 2021-03-31 | Rs26.38 Billion ≈ $285.24 Million |
+32.59% |
| 2020-03-31 | Rs19.89 Billion ≈ $215.12 Million |
+23.55% |
| 2019-03-31 | Rs16.10 Billion ≈ $174.12 Million |
+7.40% |
| 2018-03-31 | Rs14.99 Billion ≈ $162.13 Million |
+8.96% |
| 2017-03-31 | Rs13.76 Billion ≈ $148.79 Million |
+34.12% |
| 2016-03-31 | Rs10.26 Billion ≈ $110.94 Million |
+13.41% |
| 2015-03-31 | Rs9.05 Billion ≈ $97.82 Million |
+33.45% |
| 2014-03-31 | Rs6.78 Billion ≈ $73.30 Million |
+22.92% |
| 2013-03-31 | Rs5.51 Billion ≈ $59.63 Million |
+27.32% |
| 2012-03-31 | Rs4.33 Billion ≈ $46.84 Million |
+24.96% |
| 2011-03-31 | Rs3.47 Billion ≈ $37.48 Million |
+32.90% |
| 2010-03-31 | Rs2.61 Billion ≈ $28.20 Million |
+18.11% |
| 2009-03-31 | Rs2.21 Billion ≈ $23.88 Million |
+22.33% |
| 2008-03-31 | Rs1.80 Billion ≈ $19.52 Million |
+181.02% |
| 2007-03-31 | Rs642.29 Million ≈ $6.95 Million |
+41.55% |
| 2006-03-31 | Rs453.74 Million ≈ $4.91 Million |
-- |
About Shilpa Medicare Limited
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, … Read more